

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

Information for the public

Published: 29 July 2024

www.nice.org.uk

Trastuzumab deruxtecan (Enhertu) is not normally available on the NHS for treating HER2-low metastatic or unresectable breast cancer in adults:

- after chemotherapy for metastatic cancer or
- if the cancer has recurred during adjuvant chemotherapy or within 6 months of finishing it.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS webpages on breast cancer in women](#) and [breast cancer in men](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0808 800 6000
- [METUPUK](#), join-us@metupuk.org.uk
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6112-2